861 related articles for article (PubMed ID: 25540274)
21. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine.
Tejedor JC; Moro M; Ruiz-Contreras J; Castro J; Gómez-Campderá JA; Navarro ML; Merino JM; Martín-Ancel A; Roca J; García-del-Río M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Boceta R; García-Corbeira P; Jacquet JM; Collard A; Schuerman L;
Pediatr Infect Dis J; 2006 Aug; 25(8):713-20. PubMed ID: 16874171
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study.
Kovac M; Kostanyan L; Mesaros N; Kuriyakose S; Varman M
Hum Vaccin Immunother; 2018; 14(8):1977-1986. PubMed ID: 29630439
[TBL] [Abstract][Full Text] [Related]
23. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.
Grimprel E; von Sonnenburg F; Sänger R; Abitbol V; Wolter JM; Schuerman LM
Vaccine; 2005 May; 23(28):3657-67. PubMed ID: 15882526
[TBL] [Abstract][Full Text] [Related]
24. Safety and immunogenicity of a primary course and booster dose of a combined diphtheria, tetanus, acellular pertussis, hepatitis B and inactivated poliovirus vaccine.
Meriste S; Lutsar I; Tamm E; Willems P
Scand J Infect Dis; 2006; 38(5):350-6. PubMed ID: 16709537
[TBL] [Abstract][Full Text] [Related]
25. Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose.
Halperin SA; Donovan C; Marshall GS; Pool V; Decker MD; Johnson DR; Greenberg DP;
J Pediatric Infect Dis Soc; 2019 May; 8(2):105-114. PubMed ID: 29438562
[TBL] [Abstract][Full Text] [Related]
26. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.
Zangwill KM; Eriksen E; Lee M; Lee J; Marcy SM; Friedland LR; Weston W; Howe B; Ward JI
Pediatrics; 2008 Dec; 122(6):e1179-85. PubMed ID: 19047220
[TBL] [Abstract][Full Text] [Related]
27. Booster vaccination of pre-school children with reduced-antigen-content diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine co-administered with measles-mumps-rubella-varicella vaccine: a randomized, controlled trial in children primed according to a 2 + 1 schedule in infancy.
Ferrera G; Cuccia M; Mereu G; Icardi G; Bona G; Esposito S; Marchetti F; Messier M; Kuriyakose S; Hardt K
Hum Vaccin Immunother; 2012 Mar; 8(3):355-62. PubMed ID: 22327497
[TBL] [Abstract][Full Text] [Related]
28. A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults.
Thierry-Carstensen B; Jordan K; Uhlving HH; Dalby T; Sørensen C; Jensen AM; Heilmann C
Vaccine; 2012 Aug; 30(37):5464-71. PubMed ID: 22776216
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity and safety of a DTaP-IPV/Hib pentavalent vaccine given as primary and booster vaccinations in healthy infants and toddlers in Japan.
Nakayama T; Vidor E; Tsuzuki D; Nishina S; Sasaki T; Ishii Y; Mizukami H; Tsuge H
J Infect Chemother; 2020 Jul; 26(7):651-659. PubMed ID: 32307307
[TBL] [Abstract][Full Text] [Related]
30. Humoral immunity of dTap-IPV vaccine (REPEVAX®) administered one month after dT-IPV vaccine (REVAXIS®) in adults with unknown vaccination history.
Larnaudie S; Guiso N; Baptiste C; Desaint C; Desforges L; Lebon P; Soubeyrand B; Launay O
Hum Vaccin; 2010 Oct; 6(10):829-34. PubMed ID: 20864810
[TBL] [Abstract][Full Text] [Related]
31. Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization.
McCormack PL
Drugs; 2012 Sep; 72(13):1765-91. PubMed ID: 22931522
[TBL] [Abstract][Full Text] [Related]
32. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses.
Heininger U; ; ; Sänger R; Jacquet JM; Schuerman L
Vaccine; 2007 Jan; 25(6):1055-63. PubMed ID: 17049692
[TBL] [Abstract][Full Text] [Related]
33. Spotlight on DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa).
Dhillon S
BioDrugs; 2010 Oct; 24(5):299-302. PubMed ID: 20795752
[TBL] [Abstract][Full Text] [Related]
34. An open-label, randomized, multi-center study of the immunogenicity and safety of DTaP-IPV (Kinrix™) co-administered with MMR vaccine with or without varicella vaccine in healthy pre-school age children.
Klein NP; Weston WM; Kuriyakose S; Kolhe D; Howe B; Friedland LR; Van Der Meeren O
Vaccine; 2012 Jan; 30(3):668-74. PubMed ID: 22064267
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine.
Gimenez-Sanchez F; Kieninger DM; Kueper K; Martinon-Torres F; Bernaola E; Diez-Domingo J; Steul K; Juergens C; Gurtman A; Giardina P; Liang JZ; Gruber WC; Emini EA; Scott DA;
Vaccine; 2011 Aug; 29(35):6042-8. PubMed ID: 21704105
[TBL] [Abstract][Full Text] [Related]
36. Safety and immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B and polio combination vaccine in infants.
Yeh SH; Ward JI; Partridge S; Marcy SM; Lee H; Jing J; Curry ES; Howe BJ
Pediatr Infect Dis J; 2001 Oct; 20(10):973-80. PubMed ID: 11642632
[TBL] [Abstract][Full Text] [Related]
37. Immunological persistence in 4-6 and 7-9 year olds previously vaccinated in infancy with hexavalent DTPa-HBV-IPV/Hib.
Zinke M; Disselhoff J; ; Gartner B; Jacquet JM
Hum Vaccin; 2010 Feb; 6(2):189-93. PubMed ID: 20009522
[TBL] [Abstract][Full Text] [Related]
38. Impact of tetanus-diphtheria-acellular pertussis immunization during pregnancy on subsequent infant immunization seroresponses: follow-up from a large randomized placebo-controlled trial.
Perrett KP; Halperin SA; Nolan T; Carmona Martínez A; Martinón-Torres F; García-Sicilia J; Virta M; Vanderkooi OG; Zuccotti GV; Manzoni P; Kostanyan L; Meyer N; Ceregido MA; Cheuvart B; Kuriyakose SO; Stranak Z; Merino Arribas JM; Cilleruelo Ortega MJ; Miranda-Valdivieso M; Arias Novas B; Ramos Amador JT; Omeñaca F; Baca M; Marchisio PG; Mesaros N
Vaccine; 2020 Feb; 38(8):2105-2114. PubMed ID: 31776027
[TBL] [Abstract][Full Text] [Related]
39. Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults.
Brandon D; Kimmel M; Kuriyakose SO; Kostanyan L; Mesaros N
Vaccine; 2018 Oct; 36(42):6325-6333. PubMed ID: 30197282
[TBL] [Abstract][Full Text] [Related]
40. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity.
Ciarlet M; He S; Lai S; Petrecz M; Yuan G; Liu GF; Mikviman E; Heaton PM; Panzer F; Rose T; Koller DY; Van Damme P; Schödel F
Pediatr Infect Dis J; 2009 Mar; 28(3):177-81. PubMed ID: 19209092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
